Refine by
Drug Dose Articles & Analysis
35 news found
In today’s evolving pharmaceutical landscape, the search for new drug delivery systems (DDS) is of paramount importance to improving therapeutic outcomes. ...
The newly introduced solutions are focused on long-acting controlled-release microspheres and phase-transition microneedle patches, to meet the growing demand for novel biopharmaceuticals and biosimilars, while at the same time, improving efficacy, safety, and convenience in drug delivery. Microsphere and microneedle technologies have been gaining increasing popularity in ...
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
SERENITY III is a two-part, double-blinded, placebo-controlled pivotal study designed to evaluate BXCL501 60mcg dose for at-home use. This strategic trial design follows a Type B meeting with the U.S. Food and Drug Administration and observed dose-dependent responses in a prior Phase 1/2b study assessing a range of doses. ...
Subjects were randomized into one of two sequences (a fasted state, and a fed state [after a high-fat test meal]) and dosed with a 25mg dose of CTx-1301 The primary PK endpoints were maximum concentration (expressed as Cmax) during the first 28 hours after dosing, and the total amount of the active pharmaceutical ingredient (API), ...
Therefore, it is an important target for the development of influenza drugs. Currently, the detection of neuraminidase and neuraminidase inhibitors (NIs) utilizing fluorescent neuraminidase assay is a major strategy in studying biological processes and preventing influenza infection. ...
All arms also received low doses of steroids as background therapy. Two hundred sixty-five patients were enrolled at centers in 20 countries worldwide. ...
All arms also received low doses of steroids as background therapy. 265 patients were enrolled at centers in 20 countries worldwide. ...
LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney. The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. ...
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces that its ongoing trial of Temferon™ in glioblastoma multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM) has escalated to the next planned dose. With no ...
During the quarter ended 31 March 2022 Biotron Limited (‘Biotron’ or ‘the Company’) achieved key outcomes including: Confirmed and extended previous findings on the effectiveness of Biotron's lead antiviral drug BIT225 against SARS-CoV-2 in an animal model of human COVID-19 through demonstration of 100% survival despite administration of a lethal ...
The Phase I/II trial is an open label, two-part dose escalation and expansion study designed to define the safety and tolerability, explore predictive biomarkers and assess preliminary activity of JBI-802 in more than 100 study participants with advanced solid tumors. ...
Efficacy studies performed in a SUM-190PT breast cancer model of the Araris ADC demonstrated superior and complete tumor remission in all animals >100d even at 3x less drug dose applied vs EV. About Araris Biotech AG Araris Biotech AG is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable ...
The poster presentation highlights the company’s anti-CD79b antibody-drug conjugate (ADC) and the oral presentation, taking place during the conference’s minisymposium, will highlight late-breaking data on a Nectin-4 ADC generated using the company’s proprietary linker technology. ...
Title: “Attainment of Complete Renal Response Results in Significant Improvements in Lupus Impact Tracker in the AURORA 1 Study of Voclosporin in Lupus Nephritis” Poster number: 319 Presenting author: Meenakshi Jolly, M.D., M.S., Associate Professor, Rush University, Chicago Title: “Confirmation of the Immunosuppressive Function of Voclosporin at the Clinically Relevant Lupus ...
“After a busy 2021 with new patients dosed across three clinical trials, we acted in early January to strategically position AVROBIO for long-term success by reprioritizing our leading lysosomal disorder pipeline. ...
Melbourne, Australia – February 17, 2022 – PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that the Phase IIa study of its PA5108 Ocular Implant for the treatment of Primary ...
Key findings from the Phase 1b/2a trial include: AB-2004 was shown to have strong safety and tolerability across all dose levels, and no drug-related serious adverse events were identified. ...
“Furthermore, we observed that efficacy was maintained in combination with MMF and low-dose steroids.” Highlights of topline results from AURORA 2: In the 116 subjects in the voclosporin-treated group who enrolled in AURORA 2, mean estimated glomerular filtration rate (eGFR) was stable over 36 months. ...
Patients who completed 12 months of treatment in the Phase 3 AURORA 1 study were eligible to enroll in the AURORA 2 continuation study with the same randomized treatment of voclosporin at 23.7 mg twice daily or placebo, in combination with mycophenolate mofetil (MMF) at 1 g twice daily with either no or low-dose oral steroids, for an additional 24 months. A total of 216 LN ...